Displaying publications 1 - 20 of 51 in total

Abstract:
Sort:
  1. Lai KM, Goh BH, Lee WL
    Growth Factors, 2021 03 15;38(3-4):167-176.
    PMID: 33719806 DOI: 10.1080/08977194.2021.1895144
    Cell entry of influenza A virus (IAV) was reported to be promoted by epidermal growth factor receptor (EGFR). On the other hand, binding of heparin-binding EGF-like growth factor (HB-EGF) to EGFR leads to internalisation and degradation of the receptors. This study aimed to testify whether or not HB-EGF-induced downregulation of EGFR could attenuate IAV cell entry and subsequently diminish the infection. Immunoblotting and plaque assay revealed that HB-EGF-induced degradation of EGFR led to reduction of viral matrix 1 protein level and suppressed virion production. In addition, immunoblotting and imaging flow cytometric analysis demonstrated that IAV-induced phosphorylation of STAT1 and its localisation to nucleus in the early stage of infection were inhibited by HB-EGF treatment. This suggested the potential of HB-EGF in modulating uncontrolled and exaggerated inflammatory response caused by IAV infection. Together these findings attest the potential of HB-EGF mediated endocytosis and degradation of EGFR as a novel anti-IAV strategy.
    Matched MeSH terms: Epidermal Growth Factor*
  2. Azrina Md Ralib, Farah Nadia Mohd Hanafiah, Fatimah Dzaharudin, Muhammad Rasydan Abd Ghani, Mohd Nizamudin Ismail, Mohd Basri Mat Nor
    MyJurnal
    Kinetic estimate of GFR (keGFR) is a more accurate estimate of GFR in the
    acute settings with rapidly changing kidney functions. It takes into account the changes
    of creatinine over time, creatinine production rate, and the volume of distribution,
    however needs serial measurement of creatinine. We evaluated which methods of the
    conventional eGFR measurement best correlates with keGFR. This could assist clinicians
    in using a simpler method of calculation and is useful in the absence of serial plasma
    creatinine. (Copied from article).
    Matched MeSH terms: Receptor, Epidermal Growth Factor
  3. Guo HF, Mohd Ali R, Abd Hamid R, Chang SK, Rahman MH, Zainal Z, et al.
    Int J Low Extrem Wounds, 2022 Dec;21(4):544-554.
    PMID: 33241700 DOI: 10.1177/1534734620971066
    Our previous study has demonstrated that epidermal growth factor (EGF) with tocotrienol-rich fraction (TRF) cream formulation accelerating postburn wound healing with deep partial-thickness burn in rats. Current study was conducted to determine the gene expression levels related to burn wound healing process. A total of 180 Sprague-Dawley rats were randomly divided into 6 groups: untreated control, treated with Silverdin cream, base cream, base cream with 0.00075% EGF, base cream with 3% TRF or base cream with 0.00075% EGF, and 3% TRF, respectively. Burn wounds were created and the above-mentioned creams were applied once daily. Six animals from each group were sacrificed on days 3, 7, 11, 14, and 21 postburn. RNA was extracted from wound tissues and quantitative real-time polymerase chain reaction was performed to analyze the 9 wound healing-related genes against time postburn. Results demonstrated that topically applied EGF + TRF formulation downregulated the expression levels of IL-6 (interluekin-6), TNF-α (tumor necrosis factor-α) and iNOS (inducible nitric oxide synthase) throughout the whole healing process. TGF-β1 (transforming growth factor-β) and VEGF-A (vascular endothelial growth factor-A) were reduced on day 14 postburn. On the contrary, increased expression of Collagen-1 in the early stage of wound healing was observed with no effects on epidemal growth factor receptor (EGFR). The results showed beneficial application of EGF + TRF cream in the treatment of burn wound since it accelerated wound healing by relieving oxidative stress, decreasing inflammation, and promoting proper tissue modelling in the burn wound.
    Matched MeSH terms: Epidermal Growth Factor/pharmacology
  4. Eissazadeh S, Moeini H, Dezfouli MG, Heidary S, Nelofer R, Abdullah MP
    Braz J Microbiol, 2017 Apr-Jun;48(2):286-293.
    PMID: 27998673 DOI: 10.1016/j.bjm.2016.10.017
    This study was carried out to express human epidermal growth factor (hEGF) in Pichia pastoris GS115. For this aim, the hEGF gene was cloned into the pPIC9K expression vector, and then integrated into P. pastoris by electroporation. ELISA-based assay showed that the amount of hEGF secreted into the medium can be affected by the fermentation conditions especially by culture medium, pH and temperature. The best medium for the optimal hEGF production was BMMY buffered at a pH range of 6.0 and 7.0. The highest amount of hEGF with an average yield of 2.27μg/mL was obtained through an induction of the culture with 0.5% (v/v) methanol for 60h. The artificial neural network (ANN) analysis revealed that changes in both pH and temperature significantly affected the hEGF production with the pH change had slightly higher impact on hEGF production than variations in the temperature.
    Matched MeSH terms: Epidermal Growth Factor/genetics; Epidermal Growth Factor/secretion*
  5. Abdull Razis AF, Ismail EN, Hambali Z, Abdullah MN, Ali AM, Mohd Lila MA
    Appl Biochem Biotechnol, 2008 Mar;144(3):249-61.
    PMID: 18556814
    Recombinant human epidermal growth factor (EGF) was successfully expressed as a fusion protein in Escherichia coli system. This system was used OmpA signal sequence to produce soluble protein into the periplasm of E. coli. Human EGF (hEGF) synthesized in bacterial cell was found to be similar in size with the original protein and molecular weight approximately at 6.8 kDa. Cell proliferation assay was conducted to characterize the biological activity of hEGF on human dermal fibroblasts. The synthesized hEGF was found to be functional as compared with authentic hEGF in stimulating cell proliferation and promoting growth of cell. In comparison of biological activity between synthesized and commercial hEGF on cell proliferation, the results showed there was no significant different. This finding indicates the synthesized hEGF in E. coli system is fully bioactive in vitro.
    Matched MeSH terms: Epidermal Growth Factor/analysis; Epidermal Growth Factor/biosynthesis*; Epidermal Growth Factor/genetics; Epidermal Growth Factor/pharmacology*
  6. HENG, FONG SEOW
    MyJurnal
    Targeted therapies for cancer are designed to inhibit speci c cellular changes or signals required for tumour cells to proliferate, survive, promote angiogenesis and metastasize. Examples include trastuzumab (a monoclonal antibody that targets the human epidermal growth factor receptor 2 [HER2]), imatinib ( a small molecule inhibitor of bcl-abr, an oncogenic kinase) and cetuximab ( a monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor [EGFR]).
    Matched MeSH terms: Receptor, Epidermal Growth Factor
  7. Tiash S, Kamaruzman NIB, Chowdhury EH
    Drug Deliv, 2017 Nov;24(1):1721-1730.
    PMID: 29119846 DOI: 10.1080/10717544.2017.1396385
    Cancer cells lose their control on cell cycle by numerous genetic and epigenetic alterations. In a tumor, these cells highly express growth factor receptors (GFRs), eliciting growth, and cell division. Among the GFRs, epidermal growth factor receptor-1 (EGFR1) (Her1/ERBB1) and epidermal growth factor receptor-2 (EGFR2) (Her2/ERBB2) from epidermal growth factor (EGF) family and insulin-like growth factor-1 receptor (IGF1R) are highly expressed on breast cancer cells, thus contributing to the aggressive growth and invasiveness, have been focused in this study. Moreover, overexpression of these receptors is related to suppression of cell death and conferring resistance against the classical drugs used to treat cancer nowadays. Therefore, silencing of these GFRs-encoding genes by using selective small interfering RNAs (siRNAs) could be a powerful approach to treat breast cancer. The inorganic pH sensitive carbonate apatite nanoparticles (NPs) were used as a nano-carrier to deliver siRNA(s) against single or multiple GFR genes in breast cancer cells as well as in a mouse model of breast carcinoma. Silencing of egfr1 and erbb2 simultaneously led to a reduction in cell viability with an increase in cell death signal in the cancer cells and regression of tumor growth in vivo.
    Matched MeSH terms: Epidermal Growth Factor/metabolism; Receptor, Epidermal Growth Factor/metabolism*
  8. Jamaludin SYN, Azimi I, Davis FM, Peters AA, Gonda TJ, Thompson EW, et al.
    Oncol Lett, 2018 Apr;15(4):4289-4295.
    PMID: 29541196 DOI: 10.3892/ol.2018.7827
    CXC ligand (L)12 is a chemokine implicated in the migration, invasion and metastasis of cancer cells via interaction with its receptors CXC chemokine receptor (CXCR)4 and CXCR7. In the present study, CXCL12-mediated Ca2+signalling was compared with two basal-like breast cancer cell lines, MDA-MB-231 and MDA-MB-468, which demonstrate distinct metastatic potential. CXCL12 treatment induced Ca2+responses in the more metastatic MDA-MB-231 cells but not in the less metastatic MDA-MB-468 cells. Assessment of mRNA levels of CXCL12 receptors and their potential modulators in both cell lines revealed that CXCR4 and CXCR7 levels were increased in MDA-MB-231 cells compared with MDA-MB-468 cells. Cluster of differentiation (CD)24, the negative regulator of CXCL12 responses, demonstrated increased expression in MDA-MB-468 cells compared with MDA-MB-231 cells, and the two cell lines expressed comparable levels of hypoxia-inducible factor (HIF)2α, a CXCR4 regulator. Induction of epithelial-mesenchymal transition (EMT) by epidermal growth factor exhibited opposite effects on CXCR4 mRNA levels compared with hypoxia-induced EMT. Neither EMT inducer exhibited an effect on CXCR7 expression, however hypoxia increased HIF2α expression levels in MDA-MB-468 cells. Analysis of the gene expression profiles of breast tumours revealed that the highest expression levels of CXCR4 and CXCR7 were in the Claudin-Low molecular subtype, which is markedly associated with EMT features.
    Matched MeSH terms: Epidermal Growth Factor
  9. Liam CK, Pang YK, Poh ME
    J Thorac Oncol, 2014 Sep;9(9):e70-1.
    PMID: 25122441 DOI: 10.1097/JTO.0000000000000251
    Matched MeSH terms: Receptor, Epidermal Growth Factor/genetics*
  10. Liam CK, Wong CK, Tan JL
    J Thorac Oncol, 2014 Sep;9(9):e71-2.
    PMID: 25122442 DOI: 10.1097/JTO.0000000000000261
    Matched MeSH terms: Receptor, Epidermal Growth Factor/genetics*
  11. Kho SS, Yong MC, Chan SK, Tie ST
    Thorax, 2018 10;73(10):994-995.
    PMID: 29599199 DOI: 10.1136/thoraxjnl-2018-211729
    Matched MeSH terms: Epidermal Growth Factor/genetics
  12. Jahidin AH, Stewart TA, Thompson EW, Roberts-Thomson SJ, Monteith GR
    Biochem Biophys Res Commun, 2016 Sep 02;477(4):731-736.
    PMID: 27353380 DOI: 10.1016/j.bbrc.2016.06.127
    Two-pore channel proteins, TPC1 and TPC2, are calcium permeable ion channels found localized to the membranes of endolysosomal calcium stores. There is increasing interest in the role of TPC-mediated intracellular signaling in various pathologies; however their role in breast cancer has not been extensively evaluated. TPC1 and TPC2 mRNA was present in all non-tumorigenic and tumorigenic breast cell lines assessed. Silencing of TPC2 but not TPC1 attenuated epidermal growth factor-induced vimentin expression in MDA-MB-468 breast cancer cells. This effect was not due to a general inhibition of epithelial to mesenchymal transition (EMT) as TPC2 silencing had no effect on epidermal growth factor (EGF)-induced changes on E-cadherin expression. TPC1 and TPC2 were also shown to differentially regulate cyclopiazonic acid (CPA)-mediated changes in cytosolic free Ca(2+). These findings indicate potential differential regulation of signaling processes by TPC1 and TPC2 in breast cancer cells.
    Matched MeSH terms: Receptor, Epidermal Growth Factor/metabolism*
  13. Chan SJ, Niu W, Hayakawa K, Hamanaka G, Wang X, Cheah PS, et al.
    Stem Cells Transl Med, 2019 Dec;8(12):1242-1248.
    PMID: 31483567 DOI: 10.1002/sctm.19-0159
    Biomaterials provide novel platforms to deliver stem cell and growth factor therapies for central nervous system (CNS) repair. The majority of these approaches have focused on the promotion of neural progenitor cells and neurogenesis. However, it is now increasingly recognized that glial responses are critical for recovery in the entire neurovascular unit. In this study, we investigated the cellular effects of epidermal growth factor (EGF) containing hydrogels on primary astrocyte cultures. Both EGF alone and EGF-hydrogel equally promoted astrocyte proliferation, but EGF-hydrogels further enhanced astrocyte activation, as evidenced by a significantly elevated Glial fibrillary acidic protein (GFAP) gene expression. Thereafter, conditioned media from astrocytes activated by EGF-hydrogel protected neurons against injury and promoted synaptic plasticity after oxygen-glucose deprivation. Taken together, these findings suggest that EGF-hydrogels can shift astrocytes into neuro-supportive phenotypes. Consistent with this idea, quantitative-polymerase chain reaction (qPCR) demonstrated that EGF-hydrogels shifted astrocytes in part by downregulating potentially negative A1-like genes (Fbln5 and Rt1-S3) and upregulating potentially beneficial A2-like genes (Clcf1, Tgm1, and Ptgs2). Further studies are warranted to explore the idea of using biomaterials to modify astrocyte behavior and thus indirectly augment neuroprotection and neuroplasticity in the context of stem cell and growth factor therapies for the CNS. Stem Cells Translational Medicine 2019;8:1242&1248.
    Matched MeSH terms: Epidermal Growth Factor/pharmacology*
  14. Tai ML, Tan EC, Ang CC, Liam CK
    Singapore Med J, 2016 Sep;57(9):524-5.
    PMID: 27663211 DOI: 10.11622/smedj.2016157
    Matched MeSH terms: Receptor, Epidermal Growth Factor/metabolism
  15. Liam CK, Ruthranesan M, Lee CH, Pang YK, Chua KT, Lim BK
    Asia Pac J Clin Oncol, 2012 Sep;8(3):267-74.
    PMID: 22897510 DOI: 10.1111/j.1743-7563.2011.01509.x
    To evaluate the response and progression-free survival (PFS) of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor (EGFR) mutation status treated with gefitinib.
    Matched MeSH terms: Receptor, Epidermal Growth Factor/antagonists & inhibitors; Receptor, Epidermal Growth Factor/genetics
  16. Liam CK, Pang YK, Leow CH
    Respirology, 2006 May;11(3):287-91.
    PMID: 16635086
    To describe the efficacy of monotherapy with the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib in patients with locally advanced and metastatic primary lung adenocarcinoma.
    Matched MeSH terms: Receptor, Epidermal Growth Factor/drug effects*; Receptor, Epidermal Growth Factor/metabolism
  17. Liam CK, Pang YK, Poh ME, Kow KS, Wong CK, Varughese R
    Respirol Case Rep, 2013 Sep;1(1):20-2.
    PMID: 25473531 DOI: 10.1002/rcr2.14
    Breast metastases from non-small cell lung carcinoma are rarely reported. We report a case of a female patient with primary adenocarcinoma of the lower lobe of her right lung presenting with a massive right-sided malignant pleural effusion. The tumor harbored an epidermal growth factor receptor insertion mutation in exon 20 but was anaplastic lymphoma kinase translocation negative. She did not respond to treatment with erlotinib. First- and second-line cytotoxic chemotherapy resulted in stable disease as the best responses. She developed right breast metastasis 20 months after her initial presentation. The rarity of the condition and the likely mechanism of the breast metastasis are discussed.
    Matched MeSH terms: Receptor, Epidermal Growth Factor
  18. Tan SN, Sani D, Lim CW, Ideris A, Stanslas J, Lim CTS
    PMID: 32051689 DOI: 10.1155/2020/8068797
    Edible bird's nest (EBN) which is solidified swiftlet's saliva contains high nutritional value. It is widely consumed in countries like Malaysia, Indonesia, and Thailand. However, previous proximate analysis of Malaysia EBN was not representative of all the regions in Malaysia. In recent years, safety issues such as high nitrate and nitrite contents, presence of heavy metal, adulteration, fungal infection, and cancer cell stimulation were associated with EBN. Hence, this study aimed to determine the proximate analysis, safety profile during normal weather and hazy periods, and its effect on cancer cells stimulation in Malaysia-farmed EBN. Seven raw cleaned EBN samples were sourced from 6 different regions in Malaysia. Proximate analysis and safety profile were performed using official AOCA methods and Malaysian Standard. High protein (53.03-56.37%) and carbohydrate content (27.97-31.68%) with an acceptable level of moisture (10.8-14.04%) and ash (2.22-3.38%) were reported. A good safety profile was obtained with low nitrite and nitrate levels, with undetectable heavy metals and no significant growth of pathogenic microorganism except mould. Epidermal growth factor was detected but below the quantification level with the chicken EGF ELISA kit. The microculture tetrazolium (MTT) assay was performed for growth stimulation assessment comparing human EGF and EBN. There was no significant cell growth observed in cancer cells after EBN treatment. In conclusion, EBN Malaysia has a good nutritional profile, free of heavy metals, and an acceptable level of nitrate, nitrite, and microorganism profile except for mould contents. Furthermore, the in vitro study indicated that EBN was not associated with cancer cell growth.
    Matched MeSH terms: Epidermal Growth Factor
  19. Liu CY, Lin HF, Lai WY, Lin YY, Lin TW, Yang YP, et al.
    J Chin Med Assoc, 2022 Apr 01;85(4):409-413.
    PMID: 35383703 DOI: 10.1097/JCMA.0000000000000703
    Lung carcinoma (LC) is the third most common cancer diagnosis and accounted for the most cancer-related mortality worldwide in 2018. Based on the type of cells from which it originates, LC is commonly classified into non-small cell lung cancers (NSCLC) and small cell lung cancers (SCLC). NSCLC account for the majority of LC and can be further categories into adenocarcinoma, large cell carcinoma, and squamous cell carcinoma. Accurate classification of LC is critical for its adequate treatment and therapeutic outcome. Since NSCLC express more epidermal growth factor receptor (EGFR) with activation mutations, targeted therapy EGFR-tyrosine kinase inhibitors (TKIs) have been considered as primary option of NSCLC patients with activation EGFR mutation. In this review, we present the genetic alterations, reported mutations in EGFR, and TKIs treatment in NSCLC patients with an emphasis on the downstream signaling pathways in NSCLC progression. Among the signaling pathways identified, mitogen activation protein kinase (MAPK), known also as extracellular signal-regulated protein kinase (Erk) pathway, is the most investigated among the related pathways. EGFR activation leads to the autophosphorylation of its kinase domain and subsequent activation of Ras, phosphorylation of Raf and MEK1/2, and the activation of ERK1/2. Phosphatidylinositol 3-kinase (PI3K)/Akt is another signal pathway that regulates cell cycle and has been linked to NSCLC progression. Currently, three generations of EGFR TKIs have been developed as a first-line treatment of NSCLC patients with EGFR activation and mutation in which these treatment options will be further discussed in this review. The Supplementary Appendix for this article is available at http://links.lww.com/JCMA/A138.
    Matched MeSH terms: Epidermal Growth Factor
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links